Energy Efficient Operation of Adaptive Massive MIMO 5G HetNets
Authors:
Siddarth Marwaha,
Eduard A. Jorswieck,
Mostafa Jassim,
Thomas Kuerner,
David Lopez Perez,
Xilnli Geng,
Harvey Bao
Abstract:
For energy efficient operation of the massive multiple-input multiple-output (MIMO) networks, various aspects of energy efficiency maximization have been addressed, where a careful selection of number of active antennas has shown significant gains. Moreover, switching-off physical resource blocks (PRBs) and carrier shutdown saves energy in low load scenarios. However, the joint optimization of spe…
▽ More
For energy efficient operation of the massive multiple-input multiple-output (MIMO) networks, various aspects of energy efficiency maximization have been addressed, where a careful selection of number of active antennas has shown significant gains. Moreover, switching-off physical resource blocks (PRBs) and carrier shutdown saves energy in low load scenarios. However, the joint optimization of spectral PRB allocation and spatial layering in a heterogeneous network has not been completely solved yet. Therefore, we study a power consumption model for multi-cell multi-user massive MIMO 5G network, capturing the joint effects of both dimensions. We characterize the optimal resource allocation under practical constraints, i.e., limited number of available antennas, PRBs, base stations (BSs), and frequency bands. We observe a single spatial layer achieving lowest energy consumption in very low load scenarios, whereas, spatial layering is required in high load scenarios. Finally, we derive novel algorithms for energy efficient user to BS assignment and propose an adaptive algorithm for PRB assignment and power control. All results are illustrated by numerical system-level simulations, describing a realistic metropolis scenario. The results show that a higher frequency band should be used to support users with large rate requirements via spatial multiplexing and assigning each user maximum available PRBs.
△ Less
Submitted 10 October, 2023; v1 submitted 16 February, 2023;
originally announced February 2023.
Beyond the exome: what's next in diagnostic testing for Mendelian conditions
Authors:
Monica H. Wojcik,
Chloe M. Reuter,
Shruti Marwaha,
Medhat Mahmoud,
Michael H. Duyzend,
Hayk Barseghyan,
Bo Yuan,
Philip M. Boone,
Emily E. Groopman,
Emmanuèle C. Délot,
Deepti Jain,
Alba Sanchis-Juan,
Genomics Research to Elucidate the Genetics of Rare Diseases,
Consortium,
Lea M. Starita,
Michael Talkowski,
Stephen B. Montgomery,
Michael J. Bamshad,
Jessica X. Chong,
Matthew T. Wheeler,
Seth I. Berger,
Anne O'Donnell-Luria,
Fritz J. Sedlazeck,
Danny E. Miller
Abstract:
Despite advances in clinical genetic testing, including the introduction of exome sequencing (ES), more than 50% of individuals with a suspected Mendelian condition lack a precise molecular diagnosis. Clinical evaluation is increasingly undertaken by specialists outside of clinical genetics, often occurring in a tiered fashion and typically ending after ES. The current diagnostic rate reflects mul…
▽ More
Despite advances in clinical genetic testing, including the introduction of exome sequencing (ES), more than 50% of individuals with a suspected Mendelian condition lack a precise molecular diagnosis. Clinical evaluation is increasingly undertaken by specialists outside of clinical genetics, often occurring in a tiered fashion and typically ending after ES. The current diagnostic rate reflects multiple factors, including technical limitations, incomplete understanding of variant pathogenicity, missing genotype-phenotype associations, complex gene-environment interactions, and reporting differences between clinical labs. Maintaining a clear understanding of the rapidly evolving landscape of diagnostic tests beyond ES, and their limitations, presents a challenge for non-genetics professionals. Newer tests, such as short-read genome or RNA sequencing, can be challenging to order and emerging technologies, such as optical genome map** and long-read DNA or RNA sequencing, are not available clinically. Furthermore, there is no clear guidance on the next best steps after inconclusive evaluation. Here, we review why a clinical genetic evaluation may be negative, discuss questions to be asked in this setting, and provide a framework for further investigation, including the advantages and disadvantages of new approaches that are nascent in the clinical sphere. We present a guide for the next best steps after inconclusive molecular testing based upon phenotype and prior evaluation, including when to consider referral to a consortium such as GREGoR, which is focused on elucidating the underlying cause of rare unsolved genetic disorders.
△ Less
Submitted 18 January, 2023;
originally announced January 2023.
